Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.   The VP of Nonclinical Development leads Black Diamond Therapeutic’s research and early development non-clinical studies through early clinical development. Non-clinical studies relate to Preclinical Toxicology, Pharmacology, DMPK supporting IND readiness for pipeline candidates. This leader will contribute to fostering our culture of innovation, as well as strategi c and scientifically sound approaches for advancing novel therapies. They will work closely and collaborate with leaders across the Company including; Discovery Chemistry and Biology, Clinical Development, Clinical Operations, Program Leadership and Management, Business Development, CMC, Translational Medicine, and Regulatory groups.

Senior Director of Drug Metabolism and Pharmacokinetics Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. The successful candidate will have proven expertise and a track record in DMPK supporting small molecule R&D programs. They will have experience with working in a highly collaborative team environment, interfacing with multiple departments across the organization and developing strategic relationships with preferred vendors and consultants. The successful candidate will work closely with other nonclinical disciplines such as Medicinal Chemistry, Pharmacology and Toxicology as well as Clinical Pharmacology to ensure that nonclinical objectives for programs are achieved.